

Amendment to the Specification:

Please replace page 1, lines 6 through 16, with the following amended paragraph:

This invention relates to an artificial human antithrombin variant ~~which~~ that has a high protease inhibitory activity in the absence of heparin. More particularly, the invention relates to a human antithrombin variant having a three dimensional structure after binding to heparin, wherein the three dimensional structure of natural human antithrombin molecule is modified by a genetic engineering procedure. The variant of the invention can be used for the treatment of, for example, DIC, thrombotic diseases or gestosis.

FINNEGAN
ENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com